jaskirat
Post on 06-Apr-2018
217 Views
Preview:
TRANSCRIPT
-
8/2/2019 Jaskirat
1/16
INDUSTRY RESEARCHPRESENTATION
ON
AstraZeneca IndiaBy
Dr Jaskirat Kaur Kahai
Research Associate and Consultant @
Lobo Selection Services LLP
-
8/2/2019 Jaskirat
2/16
AstraZeneca plc.
AstraZeneca plc. is a British multinational
pharmaceutical and biologics company
headquartered in London, United Kingdom.
Created in 1999 through the merger of
Swedish Astra AB and British Zeneca Group
plc, it is the world's seventh-largest
pharmaceutical company measured byrevenues and has operations in over 100
countries.
-
8/2/2019 Jaskirat
3/16
A Brief of History ofAstraZeneca
India AstraZeneca is represented in India as two legal entities
AstraZeneca Pharma India Limited (a listed sales and marketingorganization with a strong manufacturing base in the country) andAstraZeneca India Pvt. Limited (a wholly owned subsidiary ofAstraZeneca PLC engaged primarily in research).
In 1987 Astra Research Centre India (ARCI) was set up in a buildingleased from IDL Chemicals Ltd. at Malleswaram Bangalore.
In 1997 Government of India permitted Astra AB to form 100%owned company (Astra Biochemicals Pvt. Ltd )
In 1999 Astra Research Centre India was renamed AstraZenecaResearch Foundation India to reflect its affiliation with the new
company resulting from the merger of Astra and Zeneca. In 2001 AstraZeneca Pharma India was born, following global
merger between Astra and Zeneca and becomes the first companyin the world to set up a dedicated research centre to find a cure forTuberculosis in Bangalore
-
8/2/2019 Jaskirat
4/16
A Brief of History ofAstraZeneca
India. Contd.. In 2008 Global sourcing office set up in India designed to
meet AZ Global standards.
In 2009- AstraZeneca collaborates with Jubliant Organosyson neuroscience research, discovered a drug to cure drug
resistant TB and introduced nine new medicines anddoubled its field force.
In 2010- AstraZeneca India announced investments tomodernize and increase the capacity of its manufacturingfacility, teamed up with the Global Alliance for TB to find a
cure for TB. Also, partnered with Medicines for MalariaVentures to look for a cure for malaria, with TorrentPharmaceuticals to supply branded generics ininternational markets and with Bristol Myers Squibb tolaunch a new drug to fight diabetes for Indian patients.
-
8/2/2019 Jaskirat
5/16
Management
Name Designation
D E Udwadia Chairman / Chair Person
K S Shah Director
Ian Brimicombe Director
Luigi Felice La Corte Director
Anandh Balasundaram Managing Director
-
8/2/2019 Jaskirat
6/16
Global launch
Director of Branded
Generics KumarSubramaniam
-
8/2/2019 Jaskirat
7/16
Managing DirectorAnandh Balasundaram
Lead business partnerAsia Pacific Mohan P.
Chief Financial Officer -Himanshu Agarwal
Director, Quality
Assurance andTechnical Services RV
Director StrategicPlanning Gagan Singh
Director, Supply ChainVR
Director, regulatory
Affairs PremnathShenoy
Vice President
Commercial Excellence
GM
Vice president Humanresources AM
Associate DirectorHuman Resources DM
Vice president Legal,
Chief Complianceofficer NS
Vice President
Marketing and salesGanesh Nair
Director Sales and
Marketing SanjeevPanchal
National Sales Director,
Primary care VijaySalian
Sales Director North
and East Zone RanjeetMishra
Regional Business
Manager Delhi ManojSharma
Area Business Manager Sales representative
Director Marketing,Rajeev Nagi
Associate Director ofMarketing Manish
Agrawal
Vice President Medical
Regulatory and ClinicalResearch Paurus Irani
Vice Presidentoperations UM
-
8/2/2019 Jaskirat
8/16
Director of Chemistry andMetabolic Sciences
Bheemarao Ugarkar
Associate DirectorChemistry Balachandra
Bandodkar
Team Leader Medicinal
Chemistry
Research ScientistMedicinal Chemistry
Regional Medical AffairsDirector Asia Pacific
Namrata B
Associate medicaldirector
Ashish Gulati , ParamjitSingh
General Manager andGroup Medical head
Medical services
Senior Medical advisor Regional Medical Advisor
Manager Medicalservices
-
8/2/2019 Jaskirat
9/16
Contact AstraZeneca India at
Head office and south zone - Avishkar Post box No. 2483, Off Bellary Road
Hebbal, Bangalore 560 024. Tel: +91-80- 6774 8000
North Zone Office- AstraZeneca Pharma India Limited, C 146, Okhla
Industrial Area, PHASE I,New Delhi- 110020.Tel +91- 011-26371588 OR
+91 011-26371589
West Zone Office- 401-403 Chintamani Plaza, Mohan Studio Compound,
Andheri - Kurla Road, Chakala, Andheri E, Mumbai - 400 099. Tel +91 022
- 67042596 / 28389320/ 28389302. Fax : 022 67042594.
East Zone Office- FMC Fortuna, 4th flr, A-5 234/3A, AJC Bose Road,
Kolkata 700 020, Ph : +91- 033 2283-7940/7941
-
8/2/2019 Jaskirat
10/16
AstraZeneca Pharma India Limited (AZPIL) is involved
in both the manufacturing and marketing of medicines.
Key healthcare areas products
Cardiovascular
Betaloc, Seloken XL, Imdur,
Ramace,Plendil,, Zestril, Crestor, Seloram,
Vigocil, Nitract SR; Xparin, Valfect
RespiratoryRhinocort, Mits Linctus, Bricarex &
Bricanyl, Symbicort,Clavatrol, Rhinofex
Maternal HealthcareProstodin, Cerviprime, Primiprost &
Partocin, Zoladex 3.6 mg, Gladis, Valenzia
OncologyArimidex, Nolvadex, Iressa, Casodex &
Faslodex
InfectionMeronem & Vancocin CP, Actamace,
,Enclere, Naropin
Pain Control & Anaesthesia Xylocaine & Sensorcaine, Diprivan
Gastrointestinal Neksium
Diabetes Onglyza
f A t Z
-
8/2/2019 Jaskirat
11/16
Current Turnover ofAstraZeneca
India(Dec '11)
Quarterly
(Mar '11)
YearlyNet Sales 153.48 594.03
Other Income 1.50 6.28
PBDIT 23.88 226.61
Net Profit 14.94 64.13
-
8/2/2019 Jaskirat
12/16
Unichem Labs
764.74
Novartis India 742.71
Wyeth 635.27
Claris Life 624.90
AstraZeneca 592.87
Shasun Pharma 567.13
Merck 524.76
Indoco Remedies 485.39
Ajanta Pharma 456.78
Arvind Remedies 362.44
Venus Remedies 356.68
http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/unichemlaboratories/UL02http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/clarislifesciences/CL02http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/novartisindia/NI01http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/clarislifesciences/CL02http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/wyeth/W11http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/clarislifesciences/CL02http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/clarislifesciences/CL02http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/astrazenecapharma/AZPhttp://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/shasunpharmaceuticals/SCDhttp://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/merck/M12http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/clarislifesciences/CL02http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/indocoremedies/IR05http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/clarislifesciences/CL02http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/ajantapharma/AP22http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/arvindremedies/AR06http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/clarislifesciences/CL02http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/arvindremedies/AR06http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/arvindremedies/AR06http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/arvindremedies/AR06http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/clarislifesciences/CL02http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/arvindremedies/AR06http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/arvindremedies/AR06http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/arvindremedies/AR06http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/ajantapharma/AP22http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/clarislifesciences/CL02http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/indocoremedies/IR05http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/clarislifesciences/CL02http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/merck/M12http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/shasunpharmaceuticals/SCDhttp://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/astrazenecapharma/AZPhttp://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/clarislifesciences/CL02http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/clarislifesciences/CL02http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/wyeth/W11http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/clarislifesciences/CL02http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/novartisindia/NI01http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/clarislifesciences/CL02http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/unichemlaboratories/UL02http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/unichemlaboratories/UL02http://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/unichemlaboratories/UL02 -
8/2/2019 Jaskirat
13/16
Current Turnover ofAstraZeneca
India ContdBalance Sheet (Mar '11) (In Rs Cr)
Total Share Capital 5.00
Net Worth 179.69
Total Debt 0.00Net Block 27.46
Investments 0.01
Net Current Assets 128.30
Total Assets 179.70
-
8/2/2019 Jaskirat
14/16
On Jul 29, 2010 , US Food and Drug Administration(FDA) Cardiovascular and Renal Drugs AdvisoryCommittee recommended the FDA approve
AstraZenecas investigational drug ticagrelor for thereduction of thrombotic events in patients with AcuteCoronary Syndromes (ACS).
About BRILINTA/BRILIQUE - Ticagrelor(BRILINTA/BRILIQUE) is an investigational oral
antiplatelet treatment for ACS. Ticagrelor is a direct-acting P2Y12 receptor antagonist in a chemical classcalled cyclo-pentyl-triazolo-pyrimidines (CPTPs).Ticagrelor is the first reversibly-binding oral ADPreceptor antagonist.
-
8/2/2019 Jaskirat
15/16
AstraZeneca India inNews
Shares in AstraZeneca Pharma India Ltd rose on March 6th2012, following a report in the newspaper, citing two peoplefamiliar with the matter, that its parent AstraZeneca Plc wasplanning to delist the Indian unit and was in talks with topinvestment banks.
13 th March 2012- UK's AstraZeneca has partnered with Indiabased Jubilant Life sciences and Belgium's Janssen Pharma.For Big Pharma companies, facing drying R&D pipelines andcost pressures, such an alliance could enhance R&D output,and leverage innovation outside their labs at lower costs.
On 1 March 2012- AstraZeneca announced that MedImmune,
its biologics arm, has received approval from the US Foodand Drug Administration (FDA) for FluMist Quadrivalent(Influenza Vaccine Live, Intranasal) in the prevention ofinfluenza. This marks the first four-strain influenza vaccineapproved by the FDA.
-
8/2/2019 Jaskirat
16/16
Name of the Companies with Address and Board-line contact details
Name of the Key Persons and Associations in this industry
Basic organization structure of Major potential clients with names (and preferablyMob nos.) of decision makers in each company
Current Turnover of these companies
Nature of Business (products & services)
Competitors (Classify: either Tier 1, Tier 2, Tier 3, etc, or basis product-wise, orMNC, Domestic, etc.)
Branches in India and overseas
No of Employees senior management, middle management, junior level
Equity base financial strengths, funds raised
What are the investments envisaged,
Proposed growth plans
Business Plans and Strategies
Business pain areas that need attention.
Clients and their industries
Technologies working on
Unique selling proposition of the company
Corporate brochures, press releases, balance sheets and Annual reports
No. of manufacturing facilities (if applicable)
top related